Hamza Mohamed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hamza Mohamed has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Tarek Mohamed
7 shared publicationsMohamed Ramez
6 shared publications- Mohammad Ghassab Deameh
Faculty of Medicine, Al-Balqa Applied University, As-Salt, Jordan
6 shared publications Baha’ Aldeen Bani Irshid
Urology Department, Princess Basma Teaching Hospital, Irbid, Jordan
4 shared publicationsAbdelrahman Abdelshafi
3 shared publications- Abdelrahman Abdelshafi
Faculty of Medicine, Assiut University, Assiut, Egypt
2 shared publications
Latest Publications
- 6 November 2026
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 23 (12)
Peptides for male sexual dysfunction: a systematic review of emerging evidence
Background: Sexual dysfunction remains highly prevalent among men and significantly impacts quality of life. Peptides are short chains of amino acids designed to mimic endogenous signaling molecules and modulate a variety of physiological pathways. Aim: To systematically review the available human evidence evaluating the effects of peptide and peptide-derived therapies on male sexual function, reproductive hormones, and semen parameters. Methods: A systematic review was conducted according to PRISMA guidelines. PubMed, Scopus, and Web of Science were searched. Eligible studies included randomized controlled trials, crossover studies, prospective clinical studies, and experimental physiological studies evaluating peptide-based interventions in adult men. Outcomes: Outcomes of interest included erectile function, sexual desire, orgasmic and ejaculatory outcomes, reproductive hormones, semen parameters, and adverse events. Results: Twelve studies comprising 372 male participants met inclusion criteria. Investigated peptides included melanocortin receptor agonists (PT-141/bremelanotide and Melanotan II), kisspeptin analogues, and oxytocin. Melanocortin receptor agonists demonstrated the most consistent improvements in erectile function, producing significant increases in penile rigidity and erectile duration in healthy men and men with erectile dysfunction, including sildenafil non-responders. Kisspeptin increased gonadotropin secretion, enhanced sexual brain processing, and improved penile tumescence and measures of sexual desire in men with hypoactive sexual desire disorder. Oxytocin showed mixed effects, with potential benefits on orgasm intensity, sexual satisfaction, and partner interaction, but no consistent improvements in erectile function, ejaculation latency, or semen parameters. Clinical Implications: Peptide-based interventions may influence male sexual health through distinct peripheral, central, endocrine, and relational mechanisms, offering potential adjuncts or second-line alternatives for men who have failed or are intolerant of first-line pharmacotherapy. Strengths and Limitations: Strengths include the synthesis of human clinical evidence across multiple peptide classes and principal domains of male sexual function. Overall, studies were limited by small sample sizes, heterogeneous populations, short follow-up durations, and a lack of comparative studies. Conclusion: Melanocortin receptor agonists currently have the strongest evidence for improving erectile outcomes, while kisspeptin represents a promising emerging therapy for sexual desire and reproductive endocrine modulation. However, the evidence base remains limited, and further studies are required before these therapies can be incorporated into routine clinical practice.
- 6 November 2026
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 23 (12)
Peptides for male sexual dysfunction: a systematic review of emerging evidence
Background: Sexual dysfunction remains highly prevalent among men and significantly impacts quality of life. Peptides are short chains of amino acids designed to mimic endogenous signaling molecules and modulate a variety of physiological pathways. Aim: To systematically review the available human evidence evaluating the effects of peptide and peptide-derived therapies on male sexual function, reproductive hormones, and semen parameters. Methods: A systematic review was conducted according to PRISMA guidelines. PubMed, Scopus, and Web of Science were searched. Eligible studies included randomized controlled trials, crossover studies, prospective clinical studies, and experimental physiological studies evaluating peptide-based interventions in adult men. Outcomes: Outcomes of interest included erectile function, sexual desire, orgasmic and ejaculatory outcomes, reproductive hormones, semen parameters, and adverse events. Results: Twelve studies comprising 372 male participants met inclusion criteria. Investigated peptides included melanocortin receptor agonists (PT-141/bremelanotide and Melanotan II), kisspeptin analogues, and oxytocin. Melanocortin receptor agonists demonstrated the most consistent improvements in erectile function, producing significant increases in penile rigidity and erectile duration in healthy men and men with erectile dysfunction, including sildenafil non-responders. Kisspeptin increased gonadotropin secretion, enhanced sexual brain processing, and improved penile tumescence and measures of sexual desire in men with hypoactive sexual desire disorder. Oxytocin showed mixed effects, with potential benefits on orgasm intensity, sexual satisfaction, and partner interaction, but no consistent improvements in erectile function, ejaculation latency, or semen parameters. Clinical Implications: Peptide-based interventions may influence male sexual health through distinct peripheral, central, endocrine, and relational mechanisms, offering potential adjuncts or second-line alternatives for men who have failed or are intolerant of first-line pharmacotherapy. Strengths and Limitations: Strengths include the synthesis of human clinical evidence across multiple peptide classes and principal domains of male sexual function. Overall, studies were limited by small sample sizes, heterogeneous populations, short follow-up durations, and a lack of comparative studies. Conclusion: Melanocortin receptor agonists currently have the strongest evidence for improving erectile outcomes, while kisspeptin represents a promising emerging therapy for sexual desire and reproductive endocrine modulation. However, the evidence base remains limited, and further studies are required before these therapies can be incorporated into routine clinical practice.
- 11 August 2026
- Published by Wiley in Neurourology and Urodynamics
Laparoscopic Burch Colposuspension Versus Transobturator Tape for the Treatment of Stress Urinary Incontinence in Egyptian Women: A 12‐Month Randomized Controlled Trial
Aims: This study aimed to compare the efficacy, safety, and patient‐reported outcomes of laparoscopic Burch colposuspension versus the transobturator tape (TOT) midurethral sling procedure for treating stress urinary incontinence (SUI) in Egyptian women. Methods: This was a randomized, open‐label clinical trial conducted in Assiut, Egypt between January 2021 and December 2023. Fifty‐two women with SUI were randomly assigned to two groups of 26 patients each: Group A underwent the TOT procedure, and Group B underwent laparoscopic Burch colposuspension. The primary outcome was the improvement of SUI, assessed by a cough stress test. Secondary outcomes included changes in symptom severity and quality of life, measured by the Urogenital Distress Inventory (UDI‐6) and the Incontinence Impact Questionnaire (IIQ‐7). Patients were evaluated at 3, 6, and 12 months postoperatively. Results: Operative and anesthesia times were significantly longer for the laparoscopic colposuspension group ( p < 0.001). At 12 months, the treatment failure rate was significantly higher in the colposuspension group (34.6%) compared to the TOT group (7.7%) ( p = 0.017). While both groups initially improved, the SUI subscale scores on the UDI‐6 for the colposuspension group worsened after 3 months, becoming significantly worse than the TOT group at 6 and 12 months ( p = 0.004 at 12 months). Similarly, at 12 months, the TOT group reported significantly better quality‐of‐life scores on the IIQ‐7 ( p = 0.04). Multivariate binary logistic regression identified laparoscopic Burch colposuspension as a significant predictor of treatment failure (Odds Ratio: 7.02, p = 0.01). Overactive bladder was more common after TOT, whereas recurrence was more frequent after colposuspension ( p = 0.02). Conclusions: While both procedures initially improve SUI, the TOT procedure provides superior and more sustained efficacy over a 12‐month period in this cohort of Egyptian women. The TOT group had a significantly lower treatment failure rate and better patient‐reported quality‐of‐life outcomes. Although associated with de novo overactive bladder and groin pain, the higher success rate of TOT suggests it may be a more reliable surgical option for SUI. ClinicalTrials.gov registration number: NCT04775186.
- 11 August 2026
- Published by Wiley in Neurourology and Urodynamics
Laparoscopic Burch Colposuspension Versus Transobturator Tape for the Treatment of Stress Urinary Incontinence in Egyptian Women: A 12‐Month Randomized Controlled Trial
Aims: This study aimed to compare the efficacy, safety, and patient‐reported outcomes of laparoscopic Burch colposuspension versus the transobturator tape (TOT) midurethral sling procedure for treating stress urinary incontinence (SUI) in Egyptian women. Methods: This was a randomized, open‐label clinical trial conducted in Assiut, Egypt between January 2021 and December 2023. Fifty‐two women with SUI were randomly assigned to two groups of 26 patients each: Group A underwent the TOT procedure, and Group B underwent laparoscopic Burch colposuspension. The primary outcome was the improvement of SUI, assessed by a cough stress test. Secondary outcomes included changes in symptom severity and quality of life, measured by the Urogenital Distress Inventory (UDI‐6) and the Incontinence Impact Questionnaire (IIQ‐7). Patients were evaluated at 3, 6, and 12 months postoperatively. Results: Operative and anesthesia times were significantly longer for the laparoscopic colposuspension group ( p < 0.001). At 12 months, the treatment failure rate was significantly higher in the colposuspension group (34.6%) compared to the TOT group (7.7%) ( p = 0.017). While both groups initially improved, the SUI subscale scores on the UDI‐6 for the colposuspension group worsened after 3 months, becoming significantly worse than the TOT group at 6 and 12 months ( p = 0.004 at 12 months). Similarly, at 12 months, the TOT group reported significantly better quality‐of‐life scores on the IIQ‐7 ( p = 0.04). Multivariate binary logistic regression identified laparoscopic Burch colposuspension as a significant predictor of treatment failure (Odds Ratio: 7.02, p = 0.01). Overactive bladder was more common after TOT, whereas recurrence was more frequent after colposuspension ( p = 0.02). Conclusions: While both procedures initially improve SUI, the TOT procedure provides superior and more sustained efficacy over a 12‐month period in this cohort of Egyptian women. The TOT group had a significantly lower treatment failure rate and better patient‐reported quality‐of‐life outcomes. Although associated with de novo overactive bladder and groin pain, the higher success rate of TOT suggests it may be a more reliable surgical option for SUI. ClinicalTrials.gov registration number: NCT04775186.
- Open Access
- 21 July 2026
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 20 (11)
Distinct predictors of stress versus urge urinary incontinence after transurethral prostatectomy
Introduction: Urinary incontinence (UI) remains a distressing complication following surgical treatment of benign prostatic hyperplasia (BPH). Although postoperative UI is well described, few prospective studies have distinguished predictors of stress urinary incontinence (SUI) from those of urge urinary incontinence (UUI). Methods: In this prospective cohort study (July 2022–July 2024), 133 men undergoing bipolar transurethral resection of the prostate (B-TURP) or bipolar enucleation of the prostate (BipolEP) were followed-up for ≥ 1 year. Preoperative and intraoperative variables were evaluated using univariate testing and multivariable logistic regression to identify independent predictors of persistent SUI and UUI. Results: SUI occurred in 20.3% of patients and was independently associated with older age and use of the enucleation technique with additional univariate associations observed for larger prostate volume, lower baseline Qmax, and greater resected tissue weight. UUI occurred in 15.8% and was independently predicted by higher IPSS scores and preoperative detrusor overactivity with univariate association also noted for older age; no intraoperative factor predicted UUI. Conclusions: SUI is primarily driven by anatomical and surgical factors, whereas UUI reflects underlying bladder dysfunction. Differentiating these predictive profiles supports individualized patient counseling, procedural planning, and preoperative risk stratification for men undergoing transurethral prostatectomy.
- 21 July 2026
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 20 (11)
Open AccessDistinct predictors of stress versus urge urinary incontinence after transurethral prostatectomy
Introduction: Urinary incontinence (UI) remains a distressing complication following surgical treatment of benign prostatic hyperplasia (BPH). Although postoperative UI is well described, few prospective studies have distinguished predictors of stress urinary incontinence (SUI) from those of urge urinary incontinence (UUI). Methods: In this prospective cohort study (July 2022–July 2024), 133 men undergoing bipolar transurethral resection of the prostate (B-TURP) or bipolar enucleation of the prostate (BipolEP) were followed-up for ≥ 1 year. Preoperative and intraoperative variables were evaluated using univariate testing and multivariable logistic regression to identify independent predictors of persistent SUI and UUI. Results: SUI occurred in 20.3% of patients and was independently associated with older age and use of the enucleation technique with additional univariate associations observed for larger prostate volume, lower baseline Qmax, and greater resected tissue weight. UUI occurred in 15.8% and was independently predicted by higher IPSS scores and preoperative detrusor overactivity with univariate association also noted for older age; no intraoperative factor predicted UUI. Conclusions: SUI is primarily driven by anatomical and surgical factors, whereas UUI reflects underlying bladder dysfunction. Differentiating these predictive profiles supports individualized patient counseling, procedural planning, and preoperative risk stratification for men undergoing transurethral prostatectomy.
- Open Access
- 30 June 2026
- Published by Oxford University Press (OUP) in Sexual Medicine Reviews
- Vol. 14 (3)
Impact of convective water vapor thermal therapy (Rezum) on male sexual function: a systematic review and meta-analysis
Background: Benign prostatic hyperplasia (BPH) is highly prevalent among aging men, with management often requiring a balance between symptom relief and preservation of sexual function. Convective water vapor thermal therapy (Rezūm) has emerged as a minimally invasive treatment; however, its effects on sexual function remain incompletely defined. This systematic review and meta-analysis evaluated the impact of Rezūm therapy on erectile and ejaculatory function. Methods: A systematic search of PubMed, Web of Science, and Scopus was conducted from inception to October 2025 in accordance with PRISMA guidelines. Studies reporting pre- and postoperative sexual function outcomes using validated instruments were included. To prevent metric mixing, the International Index of Erectile Function (IIEF) data were stratified into 3 distinct instrument frameworks: Group A (True IIEF-5; 0-25 scale), Group B (IIEF-15 Total Score; 0-75 scale), and Group C (IIEF-Erectile Function Domain; 0-30 scale), alongside the Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MSHQ-EjD) score and bother domains. Pooled mean differences (MDs) with 95% confidence intervals (CIs) were calculated using random-effects models, stratified by follow-up duration. Results: Fourteen unique studies comprising 1306 patients were included. Group A (True IIEF-5) scores demonstrated stable erectile function postoperatively, with a significant improvement observed only at 12 months (MD = 1.09; 95% CI, 0.02-2.15; P = .046; I2 = 77.2%); however, this finding did not persist under risk-of-bias-restricted (MD = 0.08; P = .85; I2 = 0%) or r = 0.5 sensitivity analyses (P = .056). Group B (IIEF-15 Total Score) showed no significant change from baseline in the primary pooled analyses at any follow-up interval. However, sensitivity analyses excluding a heterogeneity-driving outlier revealed significant improvements at 3 months (MD = 2.58; 95% CI, 0.01-5.15; P = .049; I2 = 15.7%), 6 months (MD = 5.21; 95% CI, 2.50-7.93; P = .0002; I2 = 0%), and 12 months (MD = 3.09; 95% CI, 0.56-5.61; P = .017; I2 = 0%). Group C (IIEF-Erectile Function domain) scores demonstrated preservation of erectile function through 24 months (all P > .05), despite a transient decline observed in a single cohort at 1 month. Male Sexual Health Questionnaire for Ejaculatory Dysfunction Bother scores demonstrated a significant and sustained reduction in ejaculatory distress from 1 month (MD = −0.35; P = .016) through 12 months (MD = −0.78; P = .0018), while MSHQ-EjD Score outcomes remained largely stable over time. Conclusion: Rezūm therapy demonstrates a favorable sexual safety profile, with preservation of erectile and ejaculatory function. These findings support its role as an effective minimally invasive treatment for BPH, particularly in patients prioritizing sexual function preservation.
- 30 June 2026
- Published by Oxford University Press (OUP) in Sexual Medicine Reviews
- Vol. 14 (3)
Open AccessImpact of convective water vapor thermal therapy (Rezum) on male sexual function: a systematic review and meta-analysis
Background: Benign prostatic hyperplasia (BPH) is highly prevalent among aging men, with management often requiring a balance between symptom relief and preservation of sexual function. Convective water vapor thermal therapy (Rezūm) has emerged as a minimally invasive treatment; however, its effects on sexual function remain incompletely defined. This systematic review and meta-analysis evaluated the impact of Rezūm therapy on erectile and ejaculatory function. Methods: A systematic search of PubMed, Web of Science, and Scopus was conducted from inception to October 2025 in accordance with PRISMA guidelines. Studies reporting pre- and postoperative sexual function outcomes using validated instruments were included. To prevent metric mixing, the International Index of Erectile Function (IIEF) data were stratified into 3 distinct instrument frameworks: Group A (True IIEF-5; 0-25 scale), Group B (IIEF-15 Total Score; 0-75 scale), and Group C (IIEF-Erectile Function Domain; 0-30 scale), alongside the Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MSHQ-EjD) score and bother domains. Pooled mean differences (MDs) with 95% confidence intervals (CIs) were calculated using random-effects models, stratified by follow-up duration. Results: Fourteen unique studies comprising 1306 patients were included. Group A (True IIEF-5) scores demonstrated stable erectile function postoperatively, with a significant improvement observed only at 12 months (MD = 1.09; 95% CI, 0.02-2.15; P = .046; I2 = 77.2%); however, this finding did not persist under risk-of-bias-restricted (MD = 0.08; P = .85; I2 = 0%) or r = 0.5 sensitivity analyses (P = .056). Group B (IIEF-15 Total Score) showed no significant change from baseline in the primary pooled analyses at any follow-up interval. However, sensitivity analyses excluding a heterogeneity-driving outlier revealed significant improvements at 3 months (MD = 2.58; 95% CI, 0.01-5.15; P = .049; I2 = 15.7%), 6 months (MD = 5.21; 95% CI, 2.50-7.93; P = .0002; I2 = 0%), and 12 months (MD = 3.09; 95% CI, 0.56-5.61; P = .017; I2 = 0%). Group C (IIEF-Erectile Function domain) scores demonstrated preservation of erectile function through 24 months (all P > .05), despite a transient decline observed in a single cohort at 1 month. Male Sexual Health Questionnaire for Ejaculatory Dysfunction Bother scores demonstrated a significant and sustained reduction in ejaculatory distress from 1 month (MD = −0.35; P = .016) through 12 months (MD = −0.78; P = .0018), while MSHQ-EjD Score outcomes remained largely stable over time. Conclusion: Rezūm therapy demonstrates a favorable sexual safety profile, with preservation of erectile and ejaculatory function. These findings support its role as an effective minimally invasive treatment for BPH, particularly in patients prioritizing sexual function preservation.
- Open Access
- 19 June 2026
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 7 (3) , 38
The Impact of Social Determinants of Health on Prostate Biopsy: A Systematic Review
Background/Objectives: Prostate biopsy is essential for diagnosing prostate cancer. Social determinants of health (SDOH), including socioeconomic status, race, occupation, education, and environment, affect access, outcomes, and quality of life. Recognizing disparities from technology access to complications is crucial for equitable care. A systematic review examined how SDOH impacts biopsy access, technology, and complications. Methods: A systematic search of PubMed, Web of Science, and Scopus was performed to identify eligible studies published through February 2026. We included studies that evaluated the association between one or more SDOHs and prostate biopsy. Relevant outcomes included biopsy utilization, use of specific biopsy technologies (e.g., magnetic resonance imaging (MRI)-guided, transperineal), and post-procedural complications. Results: Nine observational studies met the inclusion criteria. The findings revealed disparities across three key domains. First, access to advanced biopsy technology was uneven. Four studies showed that Black men were significantly less likely than White men to receive MRI-guided biopsies. Additionally, post-biopsy outcomes showed that Black and Hispanic men faced significantly higher rates of post-biopsy infection and hospitalization compared to White men. Lastly, patients in rural areas, those in public hospitals, and individuals with lower socioeconomic status demonstrated reduced access to modern techniques, including MRI-guided or transperineal biopsy. Conclusions: Social and economic factors influence who receives a prostate biopsy and who has access to advanced technologies. Minority and low-income patients face diagnosis barriers and higher complication rates, highlighting systemic inequities. The healthcare system often rewards access over need, and without bold policy changes, gaps in technology and resources will worsen, moving us further from truly equitable prostate cancer care.
- 19 June 2026
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 7 (3) , 38
Open AccessThe Impact of Social Determinants of Health on Prostate Biopsy: A Systematic Review
Background/Objectives: Prostate biopsy is essential for diagnosing prostate cancer. Social determinants of health (SDOH), including socioeconomic status, race, occupation, education, and environment, affect access, outcomes, and quality of life. Recognizing disparities from technology access to complications is crucial for equitable care. A systematic review examined how SDOH impacts biopsy access, technology, and complications. Methods: A systematic search of PubMed, Web of Science, and Scopus was performed to identify eligible studies published through February 2026. We included studies that evaluated the association between one or more SDOHs and prostate biopsy. Relevant outcomes included biopsy utilization, use of specific biopsy technologies (e.g., magnetic resonance imaging (MRI)-guided, transperineal), and post-procedural complications. Results: Nine observational studies met the inclusion criteria. The findings revealed disparities across three key domains. First, access to advanced biopsy technology was uneven. Four studies showed that Black men were significantly less likely than White men to receive MRI-guided biopsies. Additionally, post-biopsy outcomes showed that Black and Hispanic men faced significantly higher rates of post-biopsy infection and hospitalization compared to White men. Lastly, patients in rural areas, those in public hospitals, and individuals with lower socioeconomic status demonstrated reduced access to modern techniques, including MRI-guided or transperineal biopsy. Conclusions: Social and economic factors influence who receives a prostate biopsy and who has access to advanced technologies. Minority and low-income patients face diagnosis barriers and higher complication rates, highlighting systemic inequities. The healthcare system often rewards access over need, and without bold policy changes, gaps in technology and resources will worsen, moving us further from truly equitable prostate cancer care.
- 15 May 2026
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (7) , 215-224
Hand-sewn versus stapled ileo-ileal anastomosis following radical cystectomy: A systematic review and meta-analysis
- 15 May 2026
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (7) , 215-224
Hand-sewn versus stapled ileo-ileal anastomosis following radical cystectomy: A systematic review and meta-analysis
- 2 May 2026
- Published by Elsevier in Journal of Pediatric Urology
- p. 105992
Suprapubic versus transurethral diversion after hypospadias repair: A systematic review and meta-analysis
- 2 May 2026
- Published by Elsevier in Journal of Pediatric Urology
- p. 105992
Suprapubic versus transurethral diversion after hypospadias repair: A systematic review and meta-analysis
- Open Access
- 15 January 2026
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 411 (1)
Optimal duration of perioperative antibiotics in radical cystectomy and urinary diversion: a systematic review and meta-analysis
Purpose: To evaluate the impact of extended versus nonextended perioperative antibiotic prophylaxis (PAP) on reducing postoperative complications and hospital stays in patients undergoing radical cystectomy and urinary diversion. Methods: We conducted this systematic review and meta-analysis in accordance with the PRISMA guidelines. A comprehensive literature search was conducted across PubMed, Scopus, Web of Science, and the Cochrane Library for studies comparing short-term (≤ 24 h) and extended (≥ 24 h) PAP in patients undergoing radical cystectomy and urinary diversion. The primary outcomes were surgical site infections (SSIs), urinary tract infections (UTIs), and length of hospital stay. The statistical analysis was performed via RevMan version 5.3. The results are presented as risk ratios (RRs) and mean differences (MDs). Results are presented as risk ratios (RRs) and mean differences (MDs). The quality of evidence was assessed using the GRADE methodology. Results: A total of 214 studies were screened. Four studies involving 680 patients were included. No significant differences were detected between short-term and extended PAP in terms of SSIs (RR = 0.71 [95% CI 0.43–1.17]; P = 0.18]), febrile UTIs (RR = 1.19 [95% CI 0.91–1.56]; P = 0.20]), or length of hospital stay (MD = 0.76 days [95% CI [-2.72, 4.25]; P = 0.67]). Conclusion: No significant difference was observed between 24-h and extended PAP for reducing postoperative complications after radical cystectomy and urinary diversion. Short-term PAP is a reliable and effective strategy and is recommended as the standard practice for reducing antimicrobial resistance and improving postoperative outcomes.
- 15 January 2026
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 411 (1)
Open AccessOptimal duration of perioperative antibiotics in radical cystectomy and urinary diversion: a systematic review and meta-analysis
Purpose: To evaluate the impact of extended versus nonextended perioperative antibiotic prophylaxis (PAP) on reducing postoperative complications and hospital stays in patients undergoing radical cystectomy and urinary diversion. Methods: We conducted this systematic review and meta-analysis in accordance with the PRISMA guidelines. A comprehensive literature search was conducted across PubMed, Scopus, Web of Science, and the Cochrane Library for studies comparing short-term (≤ 24 h) and extended (≥ 24 h) PAP in patients undergoing radical cystectomy and urinary diversion. The primary outcomes were surgical site infections (SSIs), urinary tract infections (UTIs), and length of hospital stay. The statistical analysis was performed via RevMan version 5.3. The results are presented as risk ratios (RRs) and mean differences (MDs). Results are presented as risk ratios (RRs) and mean differences (MDs). The quality of evidence was assessed using the GRADE methodology. Results: A total of 214 studies were screened. Four studies involving 680 patients were included. No significant differences were detected between short-term and extended PAP in terms of SSIs (RR = 0.71 [95% CI 0.43–1.17]; P = 0.18]), febrile UTIs (RR = 1.19 [95% CI 0.91–1.56]; P = 0.20]), or length of hospital stay (MD = 0.76 days [95% CI [-2.72, 4.25]; P = 0.67]). Conclusion: No significant difference was observed between 24-h and extended PAP for reducing postoperative complications after radical cystectomy and urinary diversion. Short-term PAP is a reliable and effective strategy and is recommended as the standard practice for reducing antimicrobial resistance and improving postoperative outcomes.